Mechanisms and Treatment of Intradialytic Hypertension - Sodium

Completed

Conditions studied: Hemodialysis, End-stage Renal Disease, Hypertension, Intradialytic Hypertension

In brief

The purpose of this study is to determine the role of dialysate exposure and fluid removal during hemodialysis in the pathophysiology of intradialytic hypertension.

Key facts

Study ID

NCT01371890

Run by

University of Texas Southwestern Medical Center

People needed

18

Starts

2011-05-01

Expected to finish

2012-08-01

Last updated by the study team

2020-12-21

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• on hemodialysis > 30 days
• male and female participants, aged 18 to 85 years old, of all races and ethnic origin
• ability to provide informed consent
• Primary nephrologist deems patient is at target dry weight
• KDOQI defined hypertension (predialysis SBP >140 or postdialysis SBP>130) AND
• pre to post hemodialysis SBP increase (>10 mmHg) during 4/6 last HD session

You may not qualify if…

• Patients with active cancer or active wounds
• Patient currently on antibiotics or on IV antibiotics within the last month
• BP unable to be measured by routine mechanisms in the upper extremity
• Life expectancy < 6 months
• Inability to provide informed consent
• Larger interdialytic weight gain (>5 kg/treatment on average)

Where it is running

• UT Southwestern — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.